You are here

Azelaic Acid for Rosacea Targeted for April Launch

BERLIN, March 20 /PRNewswire-FirstCall/ -- Schering AG, Germany (FSE: SCH, NYSE: SHR) announced today that its new dermatology product Finacea™ will be launched in the U.S. market by early April 2003. Finacea™ (azelaic acid gel 15%) is Schering's new topical treatment for rosacea, a dermatological disease that affects more than 13 million American adults.

"The introduction of Finacea™ in the U.S. market is an important milestone in our strategy to globalize our Dermatology business," said Claus Zieler, Head of Dermatology at Schering AG. "We are very pleased to offer patients who suffer from rosacea a new and effective treatment option."

Simultaneously, Schering announced that its U.S. subsidiary, Berlex Laboratories Inc., has entered into an agreement with the U.S. company Allergan, Inc. for the co-promotion of Schering's Finacea™ in the U.S. market. The co-promotion agreement calls for joint sales and marketing activities for Finacea™.

Additional information

Schering received marketing approval for Finacea™ from the U.S. Food and Drug Administration (FDA) in December 2002. It was the first new therapeutic class option to be approved in the U.S. for the treatment of rosacea in more than 10 years. Finacea™ is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.

Additional data on Finacea™'s effectiveness will be presented at the venue of the annual winter meeting of the American Academy of Dermatology (AAD) in San Francisco (March 22-25, 2003).

Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology&Andrology, Diagnostics&Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for disabling diseases in the fields of the central nervous system, oncology and cardiovascular system. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work.

This press release has been published by Corporate Communication of Schering AG, Berlin, Germany.

Your contacts at Corporate Communication: Business: Dr Friedrich von Heyl, T: +49-30-468 152 96; Investor Relations: Peter Vogt, T: +49-30-468 128 38; Pharma: Dr Claudia Schmitt, T: +49-30-468 158 05, Your contacts in the U.S.: Media Relations: Kimberley Jordan, T:+1-973-487 2592, Investor Relations: Joanne Marion, T: +1-973-487 2164, Find additional information at:

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Schering AG's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Certain factors that may cause such differences are discussed in our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

Recent Headlines

Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy